Literature DB >> 16750348

Higher fasting serum insulin levels are associated with a better psychopathology profile in acutely ill non-diabetic inpatients with schizophrenia.

Xiaoduo Fan1, Emily Liu, Cynthia Pristach, Donald C Goff, David C Henderson.   

Abstract

OBJECTIVE: Recent studies have suggested a beneficial role of insulin on brain function and psychological well-being. This study was undertaken to examine whether fasting serum insulin levels are associated with the psychopathology profile in a cross-sectional sample of acutely ill non-diabetic inpatients with schizophrenia.
METHODS: Subjects were recruited from a county hospital. Each subject underwent a psychopathology assessment with the Positive and Negative Syndrome Scale (PANSS). A fasting blood sample was taken to measure serum insulin, plasma glucose and lipids.
RESULTS: Twenty-six subjects (7 females, 19 males) were included in the study. Pearson correlation analysis showed significant inverse relationships between serum insulin level and PANSS-Total, Positive Symptom subscale, and General Psychopathology subscale scores (r=-0.41, p=0.037; r=-0.49, p=0.010; r=-0.45, p=0.023, respectively). However, there was no significant relationship between serum insulin level and PANSS-Negative Symptom subscale score (r=-0.13, p=0.53). Partial correlation analysis showed that the inverse relationships between serum insulin levels and PANSS-Total, Positive Symptom subscale, and General Psychopathology subscale scores became even stronger after controlling for potential confounding variables including age, gender, race, family history of mental illness, age of illness onset and body-mass index (BMI).
CONCLUSIONS: Higher fasting serum insulin levels are associated with a better psychopathology profile in acutely ill non-diabetic inpatients with schizophrenia. It is speculated that insulin might improve clinical symptoms of schizophrenia by interacting with dopamine and other neurotransmitter systems.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16750348     DOI: 10.1016/j.schres.2006.04.010

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  5 in total

1.  Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia.

Authors:  Fernando Caravaggio; Margaret Hahn; Shinichiro Nakajima; Philip Gerretsen; Gary Remington; Ariel Graff-Guerrero
Journal:  Med Hypotheses       Date:  2015-06-24       Impact factor: 1.538

2.  S100B Serum Levels in Schizophrenia Are Presumably Related to Visceral Obesity and Insulin Resistance.

Authors:  Johann Steiner; Aye Mu Myint; Kolja Schiltz; Sabine Westphal; Hans-Gert Bernstein; Martin Walter; Matthias L Schroeter; Markus J Schwarz; Bernhard Bogerts
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-06-10

3.  Exploring the Relationship Between Body Mass Index and Positive Symptom Severity in Persons at Clinical High Risk for Psychosis.

Authors:  Fernando Caravaggio; Gary Brucato; Lawrence S Kegeles; Eugénie Lehembre-Shiah; Leigh Y Arndt; Tiziano Colibazzi; Ragy Girgis
Journal:  J Nerv Ment Dis       Date:  2017-11       Impact factor: 2.254

Review 4.  The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment.

Authors:  Alex T Raben; Victoria S Marshe; Araba Chintoh; Ilona Gorbovskaya; Daniel J Müller; Margaret K Hahn
Journal:  Front Neurosci       Date:  2018-01-22       Impact factor: 4.677

5.  Clozapine interaction with phosphatidyl inositol 3-kinase (PI3K)/insulin-signaling pathway in Caenorhabditis elegans.

Authors:  Rakesh Karmacharya; Gregory R Sliwoski; Miriam Y Lundy; Raymond F Suckow; Bruce M Cohen; Edgar A Buttner
Journal:  Neuropsychopharmacology       Date:  2009-03-25       Impact factor: 7.853

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.